Payers

Why Any Merger is the Last Resort of Lousy Marketers

Why Any Merger is the Last Resort of Lousy Marketers

By

Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?

Five things for pharma marketers to know: Friday, September 9, 2016

Five things for pharma marketers to know: Friday, September 9, 2016

By

New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit

MM&M's top 5 stories in August 2016

MM&M's top 5 stories in August 2016

By

Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer

Health exchanges, Obama administration challenged by recent insurer exits

Health exchanges, Obama administration challenged by recent insurer exits

By

The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.

Five things for pharma marketers to know: Monday, August 29, 2016

Five things for pharma marketers to know: Monday, August 29, 2016

By

Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

By

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Lobbyists create off-label principles following FDA lawsuits

Lobbyists create off-label principles following FDA lawsuits

By

PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.

Five things for pharma marketers to know: Monday, August 15, 2016

Five things for pharma marketers to know: Monday, August 15, 2016

By

Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind

Analysts: Payers moving to address MS market as prices rise

Analysts: Payers moving to address MS market as prices rise

By

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.

Five things for pharma marketers to know: Tuesday, August 9, 2016

Five things for pharma marketers to know: Tuesday, August 9, 2016

By

Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

By

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

PBMs unveil 2017 formularies, retain focus on exclusions

PBMs unveil 2017 formularies, retain focus on exclusions

By

Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.

Five things for pharma marketers to know: Tuesday, July 5, 2016

Five things for pharma marketers to know: Tuesday, July 5, 2016

By

States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO

Five things for pharma marketers to know: Wednesday, May 11, 2016

Five things for pharma marketers to know: Wednesday, May 11, 2016

By

Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies

Intouch Solutions' Weissberg on the rising payer voice

Intouch Solutions' Weissberg on the rising payer voice

By

The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

By

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Friday, March 4, 2016

Five things for pharma marketers to know: Friday, March 4, 2016

By

New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials

Five things for pharma marketers to know: Thursday, March 3, 2016

Five things for pharma marketers to know: Thursday, March 3, 2016

By

Novo's Tresiba gets non-preferred status; Valeant's head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad

Report Reflects Pharma's Strained Ties with Payers

Report Reflects Pharma's Strained Ties with Payers

By

Payer pressure was once again voted the biggest challenge by respondents, and medium and large biopharma and medical device companies appeared to be most bothered by it.

Omnicom formalizes health group led by CDM's Wise

Omnicom formalizes health group led by CDM's Wise

By

The division, dubbed Omnicom Health Group, claims to serve 70% of the top 100 pharma brands.

The New Patient Centricity Demands Clarity, Community—And Confidence

The New Patient Centricity Demands Clarity, Community—And Confidence

When it came to the issue of patient-centricity, each of us harbored at least a hint of cynicism.

Five things for pharma marketers to know: Tuesday, February 16, 2016

Five things for pharma marketers to know: Tuesday, February 16, 2016

By

Express Scripts revises PCSK9 inhibitor projections; research points to benefits of osteoporosis drugs; doctors consider emotional toll of cancer costs

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

A Competitive Market is Good for US Patients

A Competitive Market is Good for US Patients

We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.

Market Access: Looking Back, Looking Ahead

Market Access: Looking Back, Looking Ahead

Securing market access has become significantly more challenging for pharma marketers.

Healthcare industry says it struggles to define value

Healthcare industry says it struggles to define value

By

If value-based care represents the future of healthcare, it needs a better definition, attendees at an HHS forum said.

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

By

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Five things for pharma marketers to know: Friday, November 6, 2015

Five things for pharma marketers to know: Friday, November 6, 2015

By

Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky

FDA issues safety warning for AbbVie's HCV drugs

FDA issues safety warning for AbbVie's HCV drugs

By

One analyst said he expects that the change in label "will meaningfully commercially impair Viekira Pak sales."

Lilly kicks off DTC campaign for Trulicity

Lilly kicks off DTC campaign for Trulicity

By

The drugmaker aims to differentiate its type-2 diabetes drug in the competitive GLP-1 receptor agonist class.

OPINION

Email Newsletters